| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 77 | 2025 | 550 | 15.200 |
Why?
|
| Mycobacterium tuberculosis | 59 | 2026 | 430 | 10.060 |
Why?
|
| Tuberculosis, Pulmonary | 38 | 2026 | 238 | 9.530 |
Why?
|
| HIV Infections | 34 | 2026 | 2049 | 4.650 |
Why?
|
| Contact Tracing | 12 | 2025 | 61 | 4.170 |
Why?
|
| Antitubercular Agents | 33 | 2026 | 275 | 3.500 |
Why?
|
| Interferon-gamma Release Tests | 14 | 2025 | 91 | 3.110 |
Why?
|
| Tuberculin Test | 19 | 2024 | 120 | 2.590 |
Why?
|
| Latent Tuberculosis | 9 | 2019 | 75 | 2.380 |
Why?
|
| Isoniazid | 10 | 2022 | 69 | 2.250 |
Why?
|
| Sputum | 15 | 2025 | 113 | 2.170 |
Why?
|
| Sensitivity and Specificity | 26 | 2025 | 2085 | 1.950 |
Why?
|
| Feces | 10 | 2025 | 721 | 1.900 |
Why?
|
| Family Characteristics | 10 | 2021 | 93 | 1.830 |
Why?
|
| Mass Screening | 13 | 2025 | 822 | 1.780 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2026 | 86 | 1.730 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2024 | 166 | 1.700 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2025 | 526 | 1.580 |
Why?
|
| Child, Preschool | 65 | 2026 | 15110 | 1.530 |
Why?
|
| Child | 80 | 2026 | 26341 | 1.530 |
Why?
|
| Interferon-gamma | 10 | 2025 | 544 | 1.360 |
Why?
|
| Adolescent | 60 | 2026 | 20987 | 1.350 |
Why?
|
| BCG Vaccine | 10 | 2024 | 105 | 1.290 |
Why?
|
| Adoption | 5 | 2011 | 18 | 1.240 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 345 | 1.210 |
Why?
|
| Humans | 142 | 2026 | 131163 | 1.140 |
Why?
|
| Emigrants and Immigrants | 5 | 2015 | 169 | 1.120 |
Why?
|
| Infant | 46 | 2026 | 13352 | 1.050 |
Why?
|
| Diarylquinolines | 2 | 2026 | 9 | 1.050 |
Why?
|
| South Africa | 17 | 2021 | 98 | 0.970 |
Why?
|
| Disease Transmission, Infectious | 4 | 2020 | 71 | 0.880 |
Why?
|
| Transients and Migrants | 4 | 2026 | 30 | 0.880 |
Why?
|
| Rifampin | 6 | 2026 | 128 | 0.830 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2026 | 129 | 0.810 |
Why?
|
| Male | 68 | 2026 | 64957 | 0.790 |
Why?
|
| Female | 67 | 2026 | 70963 | 0.740 |
Why?
|
| Prospective Studies | 21 | 2026 | 6459 | 0.730 |
Why?
|
| HIV-1 | 3 | 2020 | 490 | 0.730 |
Why?
|
| Tanzania | 6 | 2024 | 68 | 0.720 |
Why?
|
| Global Health | 9 | 2023 | 626 | 0.710 |
Why?
|
| West Nile Fever | 4 | 2008 | 145 | 0.700 |
Why?
|
| Symptom Assessment | 1 | 2021 | 110 | 0.660 |
Why?
|
| Communicable Disease Control | 3 | 2017 | 139 | 0.650 |
Why?
|
| DNA Methylation | 3 | 2024 | 1077 | 0.610 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 787 | 0.600 |
Why?
|
| Radiography, Thoracic | 4 | 2021 | 144 | 0.590 |
Why?
|
| Orphanages | 1 | 2019 | 7 | 0.590 |
Why?
|
| Antibiotics, Antitubercular | 4 | 2025 | 38 | 0.580 |
Why?
|
| Tuberculosis, Lymph Node | 4 | 2025 | 22 | 0.580 |
Why?
|
| Lung Diseases | 1 | 2023 | 398 | 0.580 |
Why?
|
| Leukocytes | 1 | 2020 | 205 | 0.580 |
Why?
|
| Child, Orphaned | 1 | 2019 | 21 | 0.570 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1722 | 0.570 |
Why?
|
| Coinfection | 6 | 2025 | 187 | 0.550 |
Why?
|
| Young Adult | 18 | 2026 | 10103 | 0.550 |
Why?
|
| Adult | 35 | 2026 | 31282 | 0.550 |
Why?
|
| Forecasting | 2 | 2017 | 351 | 0.550 |
Why?
|
| Bacteriological Techniques | 4 | 2016 | 88 | 0.540 |
Why?
|
| Mycobacterium bovis | 3 | 2022 | 29 | 0.540 |
Why?
|
| DNA, Bacterial | 5 | 2024 | 481 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.510 |
Why?
|
| West Nile virus | 3 | 2008 | 122 | 0.510 |
Why?
|
| Medication Adherence | 1 | 2020 | 338 | 0.510 |
Why?
|
| Skin Tests | 3 | 2009 | 101 | 0.480 |
Why?
|
| Environmental Exposure | 3 | 2019 | 298 | 0.480 |
Why?
|
| Africa South of the Sahara | 5 | 2025 | 121 | 0.480 |
Why?
|
| Nutritional Status | 3 | 2017 | 298 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.460 |
Why?
|
| Pediatrics | 4 | 2018 | 1252 | 0.460 |
Why?
|
| Refugees | 2 | 2026 | 41 | 0.460 |
Why?
|
| Emigration and Immigration | 2 | 2007 | 80 | 0.450 |
Why?
|
| Masks | 2 | 2025 | 34 | 0.440 |
Why?
|
| Lipopolysaccharides | 3 | 2025 | 299 | 0.430 |
Why?
|
| HIV Seropositivity | 3 | 2021 | 123 | 0.420 |
Why?
|
| Candidiasis | 2 | 2009 | 134 | 0.410 |
Why?
|
| Age Factors | 9 | 2024 | 2825 | 0.410 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 134 | 0.400 |
Why?
|
| Tuberculosis, Meningeal | 3 | 2025 | 31 | 0.390 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.390 |
Why?
|
| Uganda | 6 | 2025 | 85 | 0.380 |
Why?
|
| Cohort Studies | 6 | 2023 | 5063 | 0.380 |
Why?
|
| Internationality | 2 | 2011 | 128 | 0.380 |
Why?
|
| Child Behavior | 3 | 2021 | 232 | 0.370 |
Why?
|
| Mozambique | 4 | 2025 | 21 | 0.370 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 58 | 0.370 |
Why?
|
| Health Personnel | 3 | 2025 | 541 | 0.360 |
Why?
|
| Models, Economic | 1 | 2012 | 59 | 0.360 |
Why?
|
| Cross-Sectional Studies | 13 | 2026 | 3829 | 0.360 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2323 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2016 | 354 | 0.340 |
Why?
|
| Antigens, Bacterial | 5 | 2025 | 319 | 0.330 |
Why?
|
| Social Stigma | 3 | 2024 | 82 | 0.330 |
Why?
|
| Ascariasis | 3 | 2018 | 76 | 0.330 |
Why?
|
| Reference Standards | 4 | 2021 | 231 | 0.320 |
Why?
|
| Infant, Newborn | 9 | 2025 | 8635 | 0.320 |
Why?
|
| Predictive Value of Tests | 6 | 2025 | 2304 | 0.320 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 141 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2025 | 401 | 0.320 |
Why?
|
| Risk Assessment | 8 | 2020 | 3711 | 0.310 |
Why?
|
| Reproducibility of Results | 5 | 2025 | 2904 | 0.310 |
Why?
|
| Qualitative Research | 3 | 2025 | 730 | 0.300 |
Why?
|
| Poliomyelitis | 1 | 2009 | 17 | 0.300 |
Why?
|
| Risk Factors | 14 | 2020 | 11074 | 0.290 |
Why?
|
| Diphtheria | 1 | 2009 | 17 | 0.290 |
Why?
|
| Retrospective Studies | 12 | 2024 | 17753 | 0.290 |
Why?
|
| Tetanus | 1 | 2009 | 23 | 0.290 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 293 | 0.290 |
Why?
|
| Measles | 1 | 2009 | 39 | 0.290 |
Why?
|
| Malnutrition | 1 | 2011 | 163 | 0.280 |
Why?
|
| Incidence | 8 | 2025 | 3360 | 0.280 |
Why?
|
| Medical Records | 1 | 2009 | 174 | 0.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2026 | 157 | 0.280 |
Why?
|
| Cost of Illness | 2 | 2020 | 297 | 0.280 |
Why?
|
| Immunologic Tests | 1 | 2008 | 18 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2026 | 889 | 0.270 |
Why?
|
| Geographic Information Systems | 1 | 2008 | 38 | 0.270 |
Why?
|
| Child Development | 1 | 2011 | 266 | 0.270 |
Why?
|
| United States | 11 | 2026 | 12072 | 0.270 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 4066 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1295 | 0.270 |
Why?
|
| Immunization | 1 | 2009 | 269 | 0.260 |
Why?
|
| Signal Transduction | 1 | 2020 | 4686 | 0.260 |
Why?
|
| Biomarkers | 5 | 2026 | 3385 | 0.260 |
Why?
|
| Schistosomiasis | 2 | 2018 | 51 | 0.260 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 327 | 0.260 |
Why?
|
| Ascaris lumbricoides | 3 | 2018 | 19 | 0.260 |
Why?
|
| Hepatitis B | 1 | 2009 | 171 | 0.260 |
Why?
|
| Environment | 1 | 2008 | 149 | 0.260 |
Why?
|
| Prevalence | 8 | 2025 | 2701 | 0.250 |
Why?
|
| Caregivers | 2 | 2024 | 598 | 0.240 |
Why?
|
| Meningitis, Viral | 1 | 2006 | 10 | 0.240 |
Why?
|
| Minors | 1 | 2026 | 6 | 0.240 |
Why?
|
| Encephalitis, Viral | 1 | 2006 | 20 | 0.240 |
Why?
|
| Logistic Models | 5 | 2020 | 1797 | 0.240 |
Why?
|
| Vaccination | 4 | 2024 | 1060 | 0.240 |
Why?
|
| Odds Ratio | 5 | 2017 | 1211 | 0.240 |
Why?
|
| Middle Aged | 14 | 2026 | 28601 | 0.230 |
Why?
|
| Viral Load | 2 | 2026 | 416 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 555 | 0.230 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2026 | 859 | 0.230 |
Why?
|
| Immune Tolerance | 2 | 2024 | 151 | 0.230 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 781 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2026 | 136 | 0.220 |
Why?
|
| Luminescent Measurements | 1 | 2025 | 55 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2025 | 146 | 0.220 |
Why?
|
| Developing Countries | 6 | 2024 | 305 | 0.220 |
Why?
|
| Disease Outbreaks | 2 | 2007 | 311 | 0.210 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 43 | 0.210 |
Why?
|
| Lesotho | 2 | 2026 | 22 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1490 | 0.210 |
Why?
|
| Health Status | 1 | 2026 | 378 | 0.200 |
Why?
|
| Philippines | 2 | 2020 | 22 | 0.200 |
Why?
|
| Ohio | 4 | 2008 | 85 | 0.200 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 14 | 0.200 |
Why?
|
| Bias | 2 | 2021 | 151 | 0.200 |
Why?
|
| Public Health | 2 | 2019 | 269 | 0.200 |
Why?
|
| Oximetry | 1 | 2024 | 176 | 0.190 |
Why?
|
| Registries | 3 | 2017 | 1634 | 0.190 |
Why?
|
| Hypoxia | 1 | 2024 | 247 | 0.190 |
Why?
|
| Th1 Cells | 2 | 2026 | 158 | 0.180 |
Why?
|
| Mental Health | 1 | 2026 | 378 | 0.180 |
Why?
|
| Levonorgestrel | 1 | 2022 | 19 | 0.180 |
Why?
|
| Child Health | 1 | 2023 | 72 | 0.180 |
Why?
|
| Aerosols | 1 | 2022 | 57 | 0.180 |
Why?
|
| Tuberculosis, Bovine | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 57 | 0.170 |
Why?
|
| HIV | 1 | 2023 | 174 | 0.170 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2021 | 16 | 0.170 |
Why?
|
| False Negative Reactions | 1 | 2021 | 89 | 0.170 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 298 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 1410 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 155 | 0.170 |
Why?
|
| False Positive Reactions | 1 | 2021 | 143 | 0.170 |
Why?
|
| Disasters | 1 | 2022 | 101 | 0.170 |
Why?
|
| Systems Biology | 1 | 2021 | 60 | 0.170 |
Why?
|
| Goals | 1 | 2022 | 126 | 0.170 |
Why?
|
| Botswana | 1 | 2021 | 76 | 0.160 |
Why?
|
| Confidence Intervals | 1 | 2021 | 272 | 0.160 |
Why?
|
| Africa | 1 | 2021 | 135 | 0.160 |
Why?
|
| Molecular Typing | 1 | 2020 | 32 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2020 | 292 | 0.160 |
Why?
|
| Cough | 1 | 2021 | 97 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 47 | 0.160 |
Why?
|
| Alanine | 1 | 2020 | 160 | 0.150 |
Why?
|
| Schistosoma | 2 | 2017 | 13 | 0.150 |
Why?
|
| Earthquakes | 1 | 2019 | 5 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2020 | 237 | 0.150 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 95 | 0.150 |
Why?
|
| Malawi | 1 | 2021 | 348 | 0.150 |
Why?
|
| Child Welfare | 2 | 2011 | 71 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2020 | 211 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 707 | 0.150 |
Why?
|
| Preventive Medicine | 1 | 2019 | 18 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 1176 | 0.150 |
Why?
|
| Chloroquine | 1 | 1999 | 30 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 166 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 919 | 0.140 |
Why?
|
| Fever | 1 | 2021 | 312 | 0.140 |
Why?
|
| Transcriptome | 2 | 2022 | 1103 | 0.140 |
Why?
|
| Weight Gain | 1 | 2021 | 393 | 0.140 |
Why?
|
| Cyclonic Storms | 1 | 2019 | 82 | 0.140 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 16 | 0.140 |
Why?
|
| Puerto Rico | 1 | 2018 | 54 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2016 | 195 | 0.130 |
Why?
|
| United Kingdom | 2 | 2023 | 267 | 0.130 |
Why?
|
| Tuberculin | 1 | 2017 | 6 | 0.130 |
Why?
|
| Health Education | 2 | 2017 | 228 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1483 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 388 | 0.120 |
Why?
|
| Attitude | 1 | 2017 | 111 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 52 | 0.120 |
Why?
|
| Helminthiasis | 1 | 2017 | 84 | 0.120 |
Why?
|
| Calibration | 1 | 2016 | 92 | 0.120 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 563 | 0.120 |
Why?
|
| Research Design | 2 | 2012 | 716 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 500 | 0.120 |
Why?
|
| Quality of Life | 1 | 2026 | 2082 | 0.120 |
Why?
|
| Antibodies, Helminth | 2 | 2016 | 131 | 0.120 |
Why?
|
| Anthelmintics | 1 | 2016 | 56 | 0.120 |
Why?
|
| Sex Factors | 1 | 2020 | 1356 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 712 | 0.120 |
Why?
|
| International Cooperation | 2 | 2011 | 165 | 0.120 |
Why?
|
| Time Factors | 3 | 2016 | 6196 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 732 | 0.110 |
Why?
|
| Housing | 2 | 2013 | 74 | 0.110 |
Why?
|
| Immunoglobulin E | 2 | 2016 | 215 | 0.110 |
Why?
|
| Comorbidity | 1 | 2020 | 1595 | 0.110 |
Why?
|
| Schools | 1 | 2017 | 239 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 101 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 254 | 0.110 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 187 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 592 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 807 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 190 | 0.110 |
Why?
|
| Somalia | 2 | 2025 | 6 | 0.110 |
Why?
|
| Resource Allocation | 1 | 2014 | 53 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 345 | 0.100 |
Why?
|
| Age Distribution | 2 | 2005 | 422 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 422 | 0.100 |
Why?
|
| Bacterial Proteins | 3 | 2026 | 953 | 0.100 |
Why?
|
| Europe | 2 | 2025 | 365 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 406 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1242 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2017 | 1240 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 61 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2025 | 3359 | 0.090 |
Why?
|
| Morbidity | 1 | 2012 | 256 | 0.090 |
Why?
|
| Markov Chains | 1 | 2012 | 101 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 667 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 151 | 0.090 |
Why?
|
| Aged | 7 | 2025 | 21025 | 0.090 |
Why?
|
| Financing, Organized | 1 | 2011 | 20 | 0.080 |
Why?
|
| World Health Organization | 2 | 2025 | 118 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2025 | 227 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 93 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 49 | 0.080 |
Why?
|
| Urban Health Services | 1 | 2010 | 15 | 0.080 |
Why?
|
| Child Health Services | 1 | 2011 | 88 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2026 | 765 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 174 | 0.080 |
Why?
|
| Russia | 1 | 2009 | 38 | 0.070 |
Why?
|
| Guatemala | 1 | 2009 | 63 | 0.070 |
Why?
|
| Documentation | 1 | 2010 | 121 | 0.070 |
Why?
|
| Consensus | 2 | 2025 | 512 | 0.070 |
Why?
|
| China | 1 | 2009 | 278 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 483 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 126 | 0.070 |
Why?
|
| Animals | 8 | 2024 | 33912 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2008 | 173 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 6797 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 71 | 0.060 |
Why?
|
| Demography | 1 | 2008 | 237 | 0.060 |
Why?
|
| Minnesota | 1 | 2007 | 178 | 0.060 |
Why?
|
| Child Nutrition Disorders | 1 | 2007 | 41 | 0.060 |
Why?
|
| Mutation | 3 | 2026 | 6099 | 0.060 |
Why?
|
| Prognosis | 1 | 2016 | 4886 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2008 | 414 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2018 | 144 | 0.060 |
Why?
|
| Asia | 2 | 2019 | 124 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1267 | 0.060 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2026 | 85 | 0.060 |
Why?
|
| Alaska | 1 | 2025 | 10 | 0.060 |
Why?
|
| Mexico | 1 | 2026 | 190 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 396 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 19 | 0.060 |
Why?
|
| Cognition | 1 | 2011 | 829 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 210 | 0.050 |
Why?
|
| Succinic Acid | 1 | 2024 | 13 | 0.050 |
Why?
|
| Succinates | 1 | 2024 | 14 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2024 | 29 | 0.050 |
Why?
|
| Microscopy | 2 | 2016 | 118 | 0.050 |
Why?
|
| Everolimus | 1 | 2024 | 50 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 387 | 0.050 |
Why?
|
| European Union | 1 | 2023 | 13 | 0.050 |
Why?
|
| Neutrophils | 1 | 2026 | 371 | 0.050 |
Why?
|
| Saliva | 1 | 2024 | 125 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 1339 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 362 | 0.050 |
Why?
|
| Poverty | 2 | 2019 | 462 | 0.050 |
Why?
|
| Urban Population | 2 | 2017 | 287 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 294 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 633 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 318 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 406 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2026 | 915 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 786 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 60 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 824 | 0.040 |
Why?
|
| Triage | 1 | 2023 | 144 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 78 | 0.040 |
Why?
|
| Oxazines | 1 | 2021 | 33 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2021 | 109 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 174 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12936 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 45 | 0.040 |
Why?
|
| Trichomonas Vaginitis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Gastrointestinal Contents | 1 | 2020 | 12 | 0.040 |
Why?
|
| Gonorrhea | 1 | 2020 | 43 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 501 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 263 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 140 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 365 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 20 | 0.040 |
Why?
|
| South America | 1 | 2019 | 45 | 0.040 |
Why?
|
| Piperazines | 1 | 2021 | 265 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 757 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 517 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 1999 | 32 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 29 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 512 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2020 | 232 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 65 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2017 | 65 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 89 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2017 | 23 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 501 | 0.030 |
Why?
|
| Malaria | 1 | 2017 | 93 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1399 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2016 | 26 | 0.030 |
Why?
|
| Phagosomes | 1 | 2016 | 38 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1680 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 96 | 0.030 |
Why?
|
| Thorax | 1 | 2015 | 63 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 332 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 217 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1717 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1489 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 214 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1626 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2016 | 192 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 136 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5196 | 0.030 |
Why?
|
| Americas | 1 | 2014 | 52 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 268 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1129 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 354 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 463 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1621 | 0.020 |
Why?
|
| Microbial Interactions | 1 | 2012 | 14 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2885 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 234 | 0.020 |
Why?
|
| Community Health Centers | 1 | 2011 | 35 | 0.020 |
Why?
|
| Medical Audit | 1 | 2011 | 98 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2465 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 151 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 254 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 86 | 0.020 |
Why?
|
| Health Resources | 1 | 2011 | 131 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1999 | 1223 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 447 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2596 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2406 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 689 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 197 | 0.020 |
Why?
|
| Clothing | 1 | 2007 | 11 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18301 | 0.020 |
Why?
|
| Insect Repellents | 1 | 2007 | 35 | 0.020 |
Why?
|
| Insecticides | 1 | 2007 | 46 | 0.020 |
Why?
|
| Television | 1 | 2007 | 70 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2007 | 96 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 2595 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4497 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 1999 | 198 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 554 | 0.010 |
Why?
|